"It is with great pleasure and anticipation that I assume my new role as Chief Editor of the Pan Cancer editorial board," said Dr. Kurzrock. "I look forward to working with my board and CollabRx staff to provide our physician colleagues with a high-level understanding of how tumor genetics are being leveraged in therapy development and to develop a best-in-class online educational resource for understanding how to use tumor genetic profiles to inform treatment planning for cancer patients."
The Pan Cancer board's initial activities will focus on the development of a Web-based application that will associate specific biomarkers with expert-vetted and clinically relevant information on drugs and clinical trials. The application functionality will be extended in stages and at launch will address sequencing-based biomarkers such as gene mutations, insertions/deletions, fusions and other aberrations. CollabRx will make a version of this application freely available online for physicians and researchers to learn about clinically actionable biomarkers in any cancer type. Subsequently, pathologists and oncologists will be able to use the application at the point of care to annotate their own data generated on any next-generation sequencing platform or sequencing-based test results obtained from any laboratory.
"The formation of a Pan Cancer editorial board illustrates our company's strategy of developing products and services for pathologists and laboratories, and it represents a significant step forward in our commitment to provide a best-in-class, expert-vetted interpretation to next-generation clinical cancer sequencing panels," said Thomas Mika, Chairman, President & Chief Executive Officer of CollabRx. "We are honored that Dr. Kurzrock and her board members are joining our large and growing expert advisory network and are working with us to assist physicians in matching patients to targeted agents based on actionable genetic aberrations."
About CollabRxCollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com . The CollabRx, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16990
CONTACT: Thomas R. Mika, CEO CollabRx, Inc. 415-248-5350 Robert Ferri Partners, LLC Robert Ferri (415) 575-1589 (direct) email@example.com
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts